These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 3261198)

  • 1. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors.
    Koller WC; Herbster G
    Clin Neuropharmacol; 1988 Jun; 11(3):221-31. PubMed ID: 3261198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats.
    Arnt J; Bøgesø KP; Hyttel J; Meier E
    Pharmacol Toxicol; 1988 Mar; 62(3):121-30. PubMed ID: 3259694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB; Criswell HE; Jensen KF; Simson PE; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1992 Aug; 262(2):855-65. PubMed ID: 1354257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement by the D1 dopamine agonist SKF 38393 of specific components of stereotypy elicited by the D2 agonists LY 171555 and RU 24213.
    Meller E; Bordi F; Bohmaker K
    Life Sci; 1988; 42(25):2561-7. PubMed ID: 3260320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists.
    Braun AR; Chase TN
    Eur J Pharmacol; 1988 Mar; 147(3):441-51. PubMed ID: 3259931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.
    Arnt J; Hyttel J
    Psychopharmacology (Berl); 1985; 85(3):346-52. PubMed ID: 2860689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
    White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ
    Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole.
    Zhou LW; Qin ZH; Weiss B
    Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
    Lublin H; Gerlach J; Peacock L
    Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats.
    Dall'Olio R; Gandolfi O; Vaccheri A; Roncada P; Montanaro N
    Psychopharmacology (Berl); 1988; 95(3):381-5. PubMed ID: 2901128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice.
    Winkler JD; Weiss B
    J Pharmacol Exp Ther; 1989 May; 249(2):507-16. PubMed ID: 2566677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
    Starr BS; Starr MS; Kilpatrick IC
    Neuroscience; 1987 Jul; 22(1):179-88. PubMed ID: 2957609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective protection from the inhibition by EEDQ of D1 and D2 dopamine agonist-induced rotational behavior in mice.
    Goodale DB; Jacobi AG; Seyfried DM; Weiss B
    Pharmacol Biochem Behav; 1988 Jun; 30(2):457-62. PubMed ID: 2902647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.
    Cory-Slechta DA; Widzowski DV; Newland MC
    J Pharmacol Exp Ther; 1989 Sep; 250(3):800-8. PubMed ID: 2789282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.